Changchun BCHT Biotechnology Co.

688276

CNE100005XY6

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 2025-01-10			5-day change	1st Jan Change
22.99 ^CNY	-1.33%		-2.83%	-8.44%

Oct. 25	Changchun BCHT Biotechnology Co. Reports Earnings Results for the Nine Months Ended September 30, 2024	CI
Aug. 16	Changchun BCHT Biotechnology H1 Profit Up 24%, Operating Income Rises 11%	MT

Changchun BCHT Biotechnology H1 Profit Up 24%, Operating Income Rises 11%

August 16, 2024 at 01:18 am EDT

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Changchun BCHT Biotechnology Co.

Changchun BCHT Biotechnology Co. Reports Earnings Results for the Nine Months Ended September 30, 2024	24-10-25	CI
Changchun BCHT Biotechnology H1 Profit Up 24%, Operating Income Rises 11%	24-08-16	MT
Changchun BCHT Biotechnology Co. Reports Earnings Results for the Half Year Ended June 30, 2024	24-08-08	CI
Chinese Drug Regulator Accepts BCHT Biotechnology's Marketing Application for Influenza Nasal Spray Vaccine	24-04-24	MT
Changchun BCHT Biotechnology Co. Reports Earnings Results for the First Quarter Ended March 31, 2024	24-04-19	CI
Changchun BCHT Biotechnology's 2023 Profit Soars 176% as Revenue Jumps 70%	24-03-20	MT
BCHT Biotechnology's 2023 Profit Surges 176%; Shares Jump 4%	24-02-26	MT
Changchun BCHT Biotechnology Co. Reports Earnings Results for the Full Year Ended December 31, 2023	24-02-23	CI
BCHT Biotechnology Gets Nod to Trial Rabies Vaccine For Humans	23-12-07	MT
Changchun High-Tech Industry's Unit Gets Nod to Trial Rabies Vaccine	23-12-07	MT
BCHT Biotechnology to Invest 805 Million Yuan in Flu Vaccine Factory	23-10-24	MT
Changchun BCHT Biotechnology Co. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-23	CI
Changchun BCHT Biotechnology Co.(XSSC:688276) added to S&P Global BMI Index	23-09-18	CI
Changchun BCHT Biotechnology Co. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-15	CI
Chuanxin Biomedical Co., Ltd. announced that it has received CNY 150 million in funding from Changchun BCHT Biotechnology Co.	23-06-28	CI

Chart Changchun BCHT Biotechnology Co.

Duration

Period

688276: Dynamic Chart

Changchun BCHT Biotechnology Co is a China-based innovative biomedical company mainly dedicated to the prevention and treatment of infectious diseases. The Company is mainly engaged in the research and development, production and sales of human vaccines. The Company has three approved vaccine products: varicella vaccine, rabies vaccine and freeze-dried nasal spray flu vaccine. The Company also has other vaccines under development and fully human monoclonal antibody under development for the prevention and control of infectious diseases. The Company mainly conducts business within the domestic market.

Employees

1,241

Sector

Pharmaceuticals

Calendar

2025-03-12 - Q4 2024 Earnings Release (Projected)

More about the company